Fresenius SE & Co KGaA (FRE)-Medical Equipment-Deals and Alliances Profile

Fresenius SE & Co KGaA (FRE)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME698D
  • |
  • Pages: 77
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; Spectra laboratories; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and postacute care hospitals in Germany through Helios Kliniken Group. Its major manufacturing plants are in the US, Germany, China, Sweden and Japan. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA (FRE)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7

Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 8

Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9

Fresenius SE & Co KGaA, Medical Equipment, Deals By Market, 2011 to YTD 2017 10

Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 11

Fresenius SE & Co KGaA, Medical Equipment, Deal Details 14

Asset Purchase 14

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 14

Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 14

Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 16

Partnerships 17

Fresenius Medical Care Extends Licensing Agreement with Interface Biologics 17

Debiotech and Fresenius Medical Care Enter into Agreement 18

Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 18

Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 19

Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 20

HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 21

Fenwal Enters Into Co-Marketing Agreement With Applied Science 21

JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 22

Fenwal Enters Into Co-Marketing Agreement With Biolog-id For RFID Blood Tracking System 23

Fenwal Enters Into Co-Marketing Agreement With Genesis BPS 24

Equity Offering 25

Fresenius Plans Private Placement Of Shares For US$1.3 Billion 25

Debt Offering 25

Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 25

Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 26

Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 27

Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 27

Fresenius Raises USD300 Million in Private Placement of Notes 28

Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 29

Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 30

Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 30

Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 31

Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 32

Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 33

Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 34

Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 35

Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 36

Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 37

Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 38

Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 39

Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 40

Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 41

Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 42

Asset Transactions 43

Fresenius Medical to Divest Dialysis Services Unit in Venezuela 43

Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 43

Acquisition 44

Fresenius Medical Care Acquires Xenios 44

Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 45

Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 46

Fresenius Medical Care to Acquire Nefrocontrol 47

Fresenius SE & Co KGaA-Key Competitors 49

Key Employees 50

Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Recent Developments 56

Strategy And Business Planning 56

Jun 08, 2017: Fresenius Medical Care sees excellent prospects for further growth and launches a new Global Efficiency Program at its Capital Markets Day 2017 56

Nov 22, 2016: HELIOS lays foundation stone for new hospital building in Wiesbaden 57

Apr 08, 2016: Fresenius Vamed lays foundation stone for new university hospital building 58

Financial Announcements 59

Oct 27, 2016: Fresenius: Continued strong sales and earnings growth; Lower end of Group earnings guidance raised 59

Aug 01, 2016: Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter 63

May 03, 2016: Strong start into the year-Double-digit earnings growth in constant currency-Fresenius confirms Group guidance for 2016 66

Feb 24, 2016: Outstanding 2015 financial results-25% dividend increase proposed-Positive outlook for 2016-New mid-term growth targets 68

Corporate Communications 72

Jan 13, 2017: Fresenius Medical Care Announces Leadership Change in North America 72

Jun 26, 2016: Fresenius appoints Stephan Sturm as new Chief Executive Officer-Ulf Mark Schneider leaves the company to pursue another opportunity 73

Legal and Regulatory 74

Jan 31, 2017: Fresenius Medical Care reaches agreement on outstanding payments 74

Jan 26, 2017: U.S. District Court Issues Preliminary Injunction Against Premium Assistance Regulation 75

Other Significant Developments 76

Aug 17, 2016: Fresenius Kabi investing nearly $250 million to expand plant near Chicago 76

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77

List of Figures

Fresenius SE & Co KGaA, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Fresenius SE & Co KGaA, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7

Fresenius SE & Co KGaA, Medical Equipment, Deals by Type, 2011 to YTD 2017 8

Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9

Fresenius SE & Co KGaA, Medical Equipment, Deals by Market, 2011 to YTD 2017 10

List of Tables

Fresenius SE & Co KGaA, Medical Equipment, Key Facts, 2016 1

Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7

Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 8

Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9

Fresenius SE & Co KGaA, Deals By Market, 2011 to YTD 2017 10

Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 11

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 14

Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 14

Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 16

Fresenius Medical Care Extends Licensing Agreement with Interface Biologics 17

Debiotech and Fresenius Medical Care Enter into Agreement 18

Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 18

Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 19

Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 20

HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 21

Fenwal Enters Into Co-Marketing Agreement With Applied Science 21

JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 22

Fenwal Enters Into Co-Marketing Agreement With Biolog-id For RFID Blood Tracking System 23

Fenwal Enters Into Co-Marketing Agreement With Genesis BPS 24

Fresenius Plans Private Placement Of Shares For US$1.3 Billion 25

Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 25

Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 26

Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 27

Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 27

Fresenius Raises USD300 Million in Private Placement of Notes 28

Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 29

Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 30

Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 30

Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 31

Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 32

Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 33

Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 34

Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 35

Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 36

Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 37

Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 38

Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 39

Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 40

Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 41

Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 42

Fresenius Medical to Divest Dialysis Services Unit in Venezuela 43

Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 43

Fresenius Medical Care Acquires Xenios 44

Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 45

Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 46

Fresenius Medical Care to Acquire Nefrocontrol 47

Fresenius SE & Co KGaA, Key Competitors 49

Fresenius SE & Co KGaA, Key Employees 50

Fresenius SE & Co KGaA, Other Locations 51

Fresenius SE & Co KGaA, Subsidiaries 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Fresenius SE & Co KGaA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16553
Site License
USD 500 INR 33105
Corporate User License
USD 750 INR 49658

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com